U.S. Markets closed

Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer

Scott Plevy, M.D. (Photo: Business Wire) Multimedia Gallery URL

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Synlogic, Inc. (SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy, M.D., as Chief Scientific Officer. Dr. Plevy will have responsibility for Synlogic’s research organization and will report to Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190409005371/en/

“Scott is a passionate physician-scientist who is driven to make a difference for patients. His expertise in gastroenterology, immunology, and microbiome science as well as his significant drug development experience will be very valuable to Synlogic as we continue to develop our Synthetic Biotic™ platform,” said Dr. Brennan. “We look forward to his leadership as we advance our platform and pipeline to achieve our mission of making a real difference for patients with few treatment options.”

“Synlogic has an exciting platform that has demonstrated the translational potential of Synthetic Biotic medicines to function in people,” stated Dr. Plevy. “I am excited to join the company’s talented team to enable development of this novel class of living medicines with potential to provide new treatment options in a broad range of metabolic diseases, immune-mediated diseases, and cancer.”

Dr. Plevy is a gastroenterologist who most recently served as Vice President, Gastroenterology Disease Area Leader and IL-23 Pathway Leader at Janssen Research & Development, LLC, after a successful career in academia. He has served as the lead investigator on multiple early-phase clinical trials, published over 100 referenced papers and articles on a breadth of topics from disease-specific targets to basic immunology and molecular biology, and performed translational research to advance the understanding of novel immunologic interventions in inflammatory bowel disease, other inflammatory conditions, and microbiome-related diseases. He earned an M.D. degree and an A.B. in mathematics from Columbia University and carried out his residency training in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Plevy replaces Dr. Paul Miller who recently joined Synlogic’s scientific advisory board.

About Synlogic
Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic™ medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. Synthetic Biotic medicines are designed to act locally and have a systemic effect to address disease in patients. Synlogic’s two lead programs, SYNB1020 and SYNB1618, are orally administered and target hyperammonemia as a result of liver damage or genetic disease, and phenylketonuria, respectively. Synlogic is also developing SYNB1891 as an intratumorally-administered Synthetic Biotic medicine for the treatment of cancer. In addition, the company is leveraging the broad potential of its platform to create additional Synthetic Biotic medicines for the treatment of liver disease, as well as inflammatory and immune disorders including Synlogic’s collaboration with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic’s platform to develop therapeutics to address a wide range of diseases, including: cancer, rare metabolic diseases, liver disease, and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic’s technology to treat cancer, hyperammonemia, and phenylketonuria. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Synlogic’s filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic’s view as of any date subsequent to the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005371/en/

MULTIMEDIA AVAILABLE:https://www.businesswire.com/news/home/20190409005371/en/